` CARM (Carisma Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

CARM
vs
S&P 500

Over the past 12 months, CARM has underperformed S&P 500, delivering a return of -51% compared to the S&P 500's 9% growth.

Stocks Performance
CARM vs S&P 500

Loading
CARM
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
CARM vs S&P 500

Performance Gap Between CARM and GSPC
HIDDEN
Show

Performance By Year
CARM vs S&P 500

Loading
CARM
S&P 500
Add Stock

Competitors Performance
Carisma Therapeutics Inc vs Peers

S&P 500
CARM
ABBV
AMGN
GILD
VRTX
Add Stock

Carisma Therapeutics Inc
Glance View

Market Cap
21m USD
Industry
Biotechnology

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. The company is headquartered in Cambridge, Massachusetts and currently employs 17 full-time employees. The company went IPO on 2014-02-06. The firm is focused on discovering and developing immunotherapies for patients with cancer and other serious disorders. Its platform is focused on engineered macrophages, cells that plays a role in both the innate and adaptive immune response. Its pipeline includes multiple chimeric antigen receptor (CAR) macrophages designed to target solid tumors by engineering a patient’s own immune cells. Its technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and cellular therapy for the treatment of human disease. The firm's pipeline includes CT-0508, CT-0525, CT-1119 and CT-0729. Its CT-0508 and CT-0525 is an ex vivo gene-modified autologous CAR-Macrophage cellular therapy to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2) metastasis. Its CT-1119 is a ex vivo gene-modified autologous CAR-Macrophage cellular therapy.

CARM Intrinsic Value
HIDDEN
Show
Back to Top